Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Abdullah M., Rani A.A., Fauzi A., Syam A.F., Makmun D., Simadibrata M., Manan C., Harjodisastro D.
7103393434;7006676360;36518523000;8443384400;16638046900;23499598400;6506149652;36518678200;
A randomized, controlled, double-blind trial of the adjunct use of Clebopride in polyethylene glycol electrolyte (PEG) solution for colonoscopy preparation.
2010
Acta medica Indonesiana
42
1
27
30
1
Department of Internal Medicine, Faculty of Medicine, University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta Pusat, 10430, Indonesia
Abdullah, M., Department of Internal Medicine, Faculty of Medicine, University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta Pusat, 10430, Indonesia; Rani, A.A.; Fauzi, A.; Syam, A.F.; Makmun, D.; Simadibrata, M.; Manan, C.; Harjodisastro, D.
AIM: To study the benefit of Clebopride as an adjuvant in polyethylene glycol electrolyte (PEG) solution for colonoscopy preparation. METHODS: Eighty one adult patients who underwent colonoscopy examination were recruited in this randomized double blind controlled study. First group received PEG and placebo, whereas second group received PEG and Clebopride. Two litres of PEG was taken at night before colonoscopy. The acceptability and tolerability of bowel preparation were assessed through interview method. The efficacy of bowel preparation was assessed using Aronchick's Criteria. RESULTS: In terms of acceptability, 64 patients (31 patients from placebo group vs 33 patients from Clebopride group) were able to drink two litres of PEG solution. Sixty patients (29 patients from placebo group and 31 patients from Clebopride group) were willing to accept PEG solution for their next bowel preparation. On the term of tolerability, nausea, abdominal distension, and borborygmus were more frequent in the placebo group (34.2% vs 27.9%; 44.7% vs 32.6%; 26.3% vs 4.6% respectively). However, only the difference at the incidence of borborygmus that was statistically significant (p<0.05). On the terms of efficacy, both groups showed a comparable bowel preparation quality with 88.4% of bowel preparation in Clebopride group and 81.6% of bowel preparation in placebo group were optimal (p = 0.585). CONCLUSION: The adjunct use of Clebopride in PEG solution for colonoscopy preparations tends to increase the acceptability, tolerability, and efficacy. The presence of borborygmus was significantly lower in the Clebopride group.
antiemetic agent; benzamide derivative; clebopride; macrogol derivative; placebo; adolescent; adult; article; chi square distribution; clinical trial; colonoscopy; controlled clinical trial; controlled study; double blind procedure; female; human; interview; male; middle aged; randomized controlled trial; solution and solubility; Adolescent; Adult; Antiemetics; Benzamides; Chi-Square Distribution; Colonoscopy; Double-Blind Method; Female; Humans; Interviews as Topic; Male; Middle Aged; Placebos; Polyethylene Glycols; Solutions
01259326
20305329
Article
Q3